EDAP TMS S.A. FOCL
3.41 USD 0.00 (+0.00%)
At closeNov 12, 2026, 4:00 PM EST
3.41 0.00 0.00%
After hours · Nov 12, 4:00 PM ET
Day range unavailable
1.95 52-week range 6.40
- YTD
- +3.65%
- 1 year
- +68.81%
News
seekingalpha.com EDAP TMS S.A. (FOCL) Presents at 2026 UBS Global Healthcare Conference Transcript EDAP TMS S.A. ( FOCL ) 2026 UBS Global Healthcare Conference November 10, 2026 1:15 PM EST Company Participants Ryan Rhodes - CEO & Director Ken Mobeck - Chief Financial Officer Presentation Unknown…
seekingalpha.com EDAP TMS S.A. (FOCL) Q3 2026 Earnings Call Transcript EDAP TMS S.A. ( FOCL ) Q3 2026 Earnings Call November 5, 2026 4:30 PM EST Company Participants Ryan Rhodes - CEO & Director Ken Mobeck - Chief Financial Officer Conference Call Participants Louisa…
benzinga.com Edap TMS Q3 2026 Earnings Call Transcript Edap TMS (NASDAQ:FOCL) reported third-quarter financial results on Thursday. The transcript from the company’s third-quarter earnings call has been provided below.This transcript is brought to you by…
benzinga.com FocalTherics Q3 EPS $(0.10) Beats $(0.25) Estimate, Sales $9.828M Miss $12.472M Estimate FocalTherics (NASDAQ:FOCL) reported quarterly losses of $(0.10) per share which beat the analyst consensus estimate of $(0.25) by 60 percent. This is a 37.5 percent increase over losses of $(0.16)…- benzinga.com HC Wainwright & Co. Reiterates Buy on Edap TMS, Maintains $10 Price Target HC Wainwright & Co. analyst Swayampakula Ramakanth reiterates Edap TMS (NASDAQ:FOCL) with a Buy and maintains $10 price target.
benzinga.com Edap TMS Q2 2026 Earnings Call: Complete Transcript Edap TMS (NASDAQ:FOCL) reported second-quarter financial results on Thursday. The transcript from the company's second-quarter earnings call has been provided below. This content is powered by…
benzinga.com FocalTherics Q2 EPS $(0.38) Misses $(0.20) Estimate, Sales $13.200M Miss $14.440M Estimate FocalTherics (NASDAQ:FOCL) reported quarterly losses of $(0.38) per share which missed the analyst consensus estimate of $(0.20) by 90 percent. This is a 123.53 percent decrease over losses of…
benzinga.com 12 Health Care Stocks Moving In Wednesday's Pre-Market Session Gainers Bone Biologics (NASDAQ:BBLG) stock moved upwards by 17.7% to $1.07 during Wednesday's pre-market session. The market value of their outstanding shares is at $1.6 million. Definium Therapeutics
benzinga.com 12 Health Care Stocks Moving In Tuesday's After-Market Session Gainers Dermata Therapeutics (NASDAQ:DRMA) stock moved upwards by 44.4% to $1.56 during Tuesday's after-market session. The company's market cap stands at $4.5 million. As per the news, the Q2…
benzinga.com FocalTherics Reports Preliminary Q2 Sales Of $12.7M-$13.2M, Up 34%-39% Year-On-Year During the second quarter of 2026, the Extracorporeal Shock Wave Lithotripsy (ESWL) and Distribution segments met the criteria to be classified as held for sale under ASC 205-20, Presentation of…- benzinga.com FocalTherics Announces Underwritten Public Offering Of ADSs The Company intends to grant the underwriters a 30-day option to purchase up to an additional 15% of the ADSs sold in the Offering on the same terms and conditions. The terms of the ADSs to be issued…
benzinga.com FocalTherics Launches First European Commercial Endometriosis Focal One Program With Treatment Of Initial Patients In Toulouse, France The hospital launched their endometriosis Focal One program following the acquisition of the system with the intention of utilizing it for treating both deep infiltrating endometriosis and prostate…
benzinga.com FocalTherics Expanding Focal One Robotic HIFU Access Under Signed Agreement With MellingMedical To Federal Healthcare Providers FocalTherics (Nasdaq: FOCL) (the "Company"), the global leader in robotic focal therapy, today announced that it has entered into an agreement with MellingMedical, a leading SBA-Verified…
benzinga.com HC Wainwright & Co. Reiterates Buy on FocalTherics, Maintains $10 Price Target HC Wainwright & Co. analyst Swayampakula Ramakanth reiterates FocalTherics (NASDAQ:FOCL) with a Buy and maintains $10 price target.